Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Arnon Nagler, Allain-Thibeault Ferhat, Didier Blaise, Yener Koc, Emanuele Angelucci, Alessandro Busca, Jiri Pavlu, Stefania Bramanti, Maija Itäla-remes, Maria Aranzazu Bermudez Rodriguez, Jan Vydra, Alexander Kulagin, Ali Bazarbachi, Bipin N. Savani, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2024-193936

Published: 2024

Journal Articles

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 3562.

https://doi.org/10.1182/blood-2024-200458

Published: 2024

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 464.

https://doi.org/10.1182/blood-2024-202279

Published: 2024

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

Blood (2024) 144 (Supplement 1): 2188.

https://doi.org/10.1182/blood-2024-200501

Published: 2024

Journal Articles

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 2185.

https://doi.org/10.1182/blood-2024-206733

Published: 2024

Journal Articles

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 2180.

https://doi.org/10.1182/blood-2024-200423

Published: 2024

Journal Articles

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 399.

https://doi.org/10.1182/blood-2024-210100

Published: 2024

Journal Articles

Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Blood (2024) 144 (Supplement 1): 749.

https://doi.org/10.1182/blood-2024-194657

Published: 2024

Journal Articles

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 693.

https://doi.org/10.1182/blood-2024-203472

Published: 2024

Journal Articles

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Blood (2024) 144 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2024-206160

Published: 2024

Journal Articles

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Blood (2024) 144 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2024-205007

Published: 2024

Journal Articles

Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

Patricia Lopez Pereira, Ali Bazarbachi, Ambroise Marçais, Maud Ngoya, Irma Khvedelidze, Ben Carpenter, Victoria Potter, Flore Sicre de Fontbrune, Alina Daniela Tanase, Lucy Cook, Francesca Kinsella, Emma Nicholson, Annoek E. C. Broers, Jennifer Clay, Sr., Hélène Labussière-Wallet, Fabio Ciceri, Bertram Glass, Olivier Hermine, Ana Maria Sureda Balari

Blood (2024) 144 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2024-207307

Published: 2024

Journal Articles

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Blood (2024) 144 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2024-204824

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4944.

https://doi.org/10.1182/blood-2024-207391

Published: 2024

Journal Articles

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2024-204672

Published: 2024

Journal Articles

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Blood (2024) 144 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2024-202764

Published: 2024

Journal Articles

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Blood (2024) 144 (Supplement 1): 6418.

https://doi.org/10.1182/blood-2024-210619

Published: 2024

Journal Articles

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Blood (2024) 144 (Supplement 1): 7418.

https://doi.org/10.1182/blood-2024-206153

Published: 2024

Journal Articles

Race and Ethnicity As a Category Poses Challenges in Global Registries: Experience from the Waustim Project of the Worldwide Network for Blood and Marrow Transplantation, WBMT

Nada Hamad, Hiroyuki Takamatsu, Luuk Gras, Linda Koster, Laurien Baaij, Anita D'Souza, Noel Estrada-Merly, Parameswaran N. Hari, Andrew J. Cowan, Wael Saber, Minako Iida, Shinichiro Okamoto, Shohei Mizuno, Koji Kawamura, Yoshihisa Kodera, Bor-Sheng Ko, KIM Wah HO, Christopher Liam, A Sim Goh, Sui Tan, Hira Mian, Ali Bazarbachi, Brig Qamar Un N Chaudhry, Rozan Alfar, Mohamed Amine Bekadja, Malek Benakli, Cristobal Augusto Frutos Ortiz, Eloisa Riva, Sebastian Galeano, Francisca Bass, Arleigh McCurdy, Alaa Elhaddad, Feng Rong Wang, Meng Lv, Mickey Boon Chai Koh, John Snowden, Stefan Schonland, Donal P McLornan, Mette Heisenberg, Patrick J Hayden, Daniel Neumann, Rafael De La Camara, Raffaella Greco, Fabio Ciceri, Anna Sureda Balari, Anna Sureda Balari, Damiano Rondelli, Hildegard T. Greinix, Mahmoud Aljurf, Yoshiko Atsuta, Dietger W. Niederwieser, Laurent Garderet

Blood (2024) 144 (Supplement 1): 7848.

https://doi.org/10.1182/blood-2024-209898

Published: 2024

NARROW

Peripheral Blood Stem Cell Versus Bone Marrow Graft for Non-T-Depleted Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Similar Transplant Outcomes for Haplo and MUD Allo-Hcts in AML Patients Achieving CR2: A Study Analyzing 4030 Allo-HCT Recipients from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Autologous and Allogeneic Stem Cell Transplantation for Major T-Cell Lymphoma Entities: An Analysis of the EBMT Lymphoma Working Party

Outcome of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia with Wilms Tumor 1 (WT1) Mutation: A Study from the ALWP/EBMT

Improved Post-Transplant Outcomes over Time for Older Patients with Acute Lymphoblastic Leukemia in First Complete Remission. a Study from the EBMT Acute Leukemia Working Party

Better Outcome Following Younger Haploidentical Donor Versus Older Matched Unrelated Donor Transplant for Patients with Acute Myeloid Leukemia in First Remission: A Study from the Global Committee and Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Hematopoietic Stem Cell Transplantation in Hepatosplenic T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

No Differences in Transplant Outcomes with Post-Transplant Cyclophosphamide in One Antigen Mismatched Unrelated Donor Compared to Matched Unrelated Donor Recipients Receiving Antithymocyte Globulin in Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Venetoclax Alone or in Combination Shows Promising Activity in Preclinical Models and Clinical Cases of Relapsed/Refractory North American Adult T-Cell Leukemia Lymphoma

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Haploidentical Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the EBMT

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

In AML Patients Allografted in First Remission, DNMT3A Mutations Differentially Affect Post-Transplant Outcomes According to Karyotype, NPM1 and FLT3-ITD Mutation Status - from the EBMT-ALWP

Mogamulizumab Shows Significant Activity with Tolerable Toxicity in a Real-World North American Adult T-Cell Leukemia/Lymphoma (ATLL) Cohort

Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy?

Race and Ethnicity As a Category Poses Challenges in Global Registries: Experience from the Waustim Project of the Worldwide Network for Blood and Marrow Transplantation, WBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only